Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 148 No. 3334 (2018)

The clinical benefit of imaging in the diagnosis and treatment of giant cell arteritis

  • Christoph T. Berger
  • Gregor Sommer
  • Markus Aschwanden
  • Daniel Staub
  • Christof Rottenburger
  • Thomas Daikeler
DOI
https://doi.org/10.4414/smw.2018.14661
Cite this as:
Swiss Med Wkly. 2018;148:w14661
Published
22.08.2018

Summary

Historically, giant cell arteritis (GCA) was considered to be synonymous with temporal arteritis. However, the disease spectrum of GCA extends much further, and includes vasculitis of the aorta and its branches with or without involvement of the temporal arteries. Imaging is crucial for the diagnosis and follow-up of GCA patients. Large vessel GCA (LV-GCA) often presents as an inflammatory syndrome and is only detected by imaging modalities such as: colour duplex sonography (CDS), computed tomography (CT) / CT angiography (CTA), magnetic resonance imaging (MRI) or 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) / CT. Deciding which imaging modality to use in different clinical situations remains a matter of debate. CDS and MRI enable assessment of the temporal arteries with a presumably higher sensitivity than histology. In the context of a typical presentation, CDS can replace a biopsy. In about a third of patients, the temporal arteries are not involved, thus PET/CT, MRI, CT, or CDS of larger arteries is needed to diagnose GCA. The sensitivity of all modalities is affected by glucocorticoid therapy. Therefore, without delaying therapy, imaging should be performed within a few days of treatment initiation. The use of PET/CT for the work-up of inflammatory syndromes in the elderly reveals vasculitis in approximately 20% of examined patients and uncover relevant diagnoses in the majority of remaining patients. The aorta should be routinely assessed in all GCA patients at diagnosis and during follow-up. MRA or CTA are best suited to characterise structural damage of larger arteries. The role of imaging in monitoring GCA disease activity still needs to be further defined.

References

  1. De Smit E, Palmer AJ, Hewitt AW. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. 2015;42(1):119–25. doi:.https://doi.org/10.3899/jrheum.140318
  2. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96–101. doi:.https://doi.org/10.1093/rheumatology/kem322
  3. Muratore F, Kermani TA, Crowson CS, Green AB, Salvarani C, Matteson EL, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford). 2015;54(3):463–70. doi:.https://doi.org/10.1093/rheumatology/keu329
  4. Muto G, Yamashita H, Takahashi Y, Miyata Y, Morooka M, Minamimoto R, et al. Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatol Int. 2014;34(11):1545–54. doi:.https://doi.org/10.1007/s00296-014-2985-3
  5. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999;42(2):311–7. doi:.https://doi.org/10.1002/1529-0131(199902)42:2<311::AID-ANR14>3.0.CO;2-F
  6. Agard C, Barrier JH, Dupas B, Ponge T, Mahr A, Fradet G, et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59(5):670–6. doi:.https://doi.org/10.1002/art.23577
  7. Aschwanden M, Kesten F, Stern M, Thalhammer C, Walker UA, Tyndall A, et al. Vascular involvement in patients with giant cell arteritis determined by duplex sonography of 2x11 arterial regions. Ann Rheum Dis. 2010;69(7):1356–9. doi:.https://doi.org/10.1136/ard.2009.122135
  8. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum. 2006;55(1):131–7. doi:.https://doi.org/10.1002/art.21699
  9. Ghinoi A, Pipitone N, Nicolini A, Boiardi L, Silingardi M, Germanò G, et al. Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology (Oxford). 2012;51(4):730–4. doi:.https://doi.org/10.1093/rheumatology/ker329
  10. Prieto-González S, Arguis P, García-Martínez A, Espígol-Frigolé G, Tavera-Bahillo I, Butjosa M, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170–6. doi:.https://doi.org/10.1136/annrheumdis-2011-200865
  11. de Boysson H, Daumas A, Vautier M, Parienti JJ, Liozon E, Lambert M, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17(4):391–8. doi:.https://doi.org/10.1016/j.autrev.2017.11.029
  12. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8. doi:.https://doi.org/10.1002/art.1780330810
  13. Craven A, Robson J, Ponte C, Grayson PC, Suppiah R, Judge A, et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol. 2013;17(5):619–21. doi:.https://doi.org/10.1007/s10157-013-0854-0
  14. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–28. doi:.https://doi.org/10.1056/NEJMoa1613849
  15. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–7. doi:.https://doi.org/10.1016/S0140-6736(16)00560-2
  16. Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9(12):731–40. doi:.https://doi.org/10.1038/nrrheum.2013.161
  17. Schmidt WA, Kraft HE, Vorpahl K, Völker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997;337(19):1336–42. doi:.https://doi.org/10.1056/NEJM199711063371902
  18. Aschwanden M, Daikeler T, Kesten F, Baldi T, Benz D, Tyndall A, et al. Temporal artery compression sign--a novel ultrasound finding for the diagnosis of giant cell arteritis. Ultraschall Med. 2013;34(1):47–50.
  19. Schäfer VS, Juche A, Ramiro S, Krause A, Schmidt WA. Ultrasound cut-off values for intima-media thickness of temporal, facial and axillary arteries in giant cell arteritis. Rheumatology (Oxford). 2017;56(9):1479–83. doi:.https://doi.org/10.1093/rheumatology/kex143
  20. Kaspar M, Partovi S, Aschwanden M, Imfeld S, Baldi T, Uthoff H, et al. Assessment of microcirculation by contrast-enhanced ultrasound: a new approach in vascular medicine. Swiss Med Wkly. 2015;145:w14047.
  21. Germanò G, Macchioni P, Possemato N, Boiardi L, Nicolini A, Casali M, et al. Contrast-Enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. Arthritis Care Res (Hoboken). 2017;69(1):143–9. doi:.https://doi.org/10.1002/acr.22906
  22. Fleischmann D, Mitchell RS, Miller DC. Acute aortic syndromes: new insights from electrocardiographically gated computed tomography. Semin Thorac Cardiovasc Surg. 2008;20(4):340–7. doi:.https://doi.org/10.1053/j.semtcvs.2008.11.011
  23. Berthod PE, Aho-Glélé S, Ornetti P, Chevallier O, Devilliers H, Ricolfi F, et al. CT analysis of the aorta in giant-cell arteritis: a case-control study. Eur Radiol. 2018. [Epub ahead of print] doi:.https://doi.org/10.1007/s00330-018-5311-8
  24. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636–43. doi:.https://doi.org/10.1136/annrheumdis-2017-212649
  25. Michaely HJ, Morelli JN, Budjan J, Riffel P, Nickel D, Kroeker R, et al. CAIPIRINHA-Dixon-TWIST (CDT)-volume-interpolated breath-hold examination (VIBE): a new technique for fast time-resolved dynamic 3-dimensional imaging of the abdomen with high spatial resolution. Invest Radiol. 2013;48(8):590–7. doi:.https://doi.org/10.1097/RLI.0b013e318289a70b
  26. Bley TA, Uhl M, Venhoff N, Thoden J, Langer M, Markl M. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol. 2007;26(3):448–50. doi:.https://doi.org/10.1007/s10067-005-0160-7
  27. Glaudemans AW, Signore A. FDG-PET/CT in infections: the imaging method of choice? Eur J Nucl Med Mol Imaging. 2010;37(10):1986–91. doi:.https://doi.org/10.1007/s00259-010-1587-x
  28. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48(1):35–45.
  29. Slart RHJA ; Writing group; Reviewer group; Members of EANM Cardiovascular; Members of EANM Infection & Inflammation; Members of Committees, SNMMI Cardiovascular; Members of Council, PET Interest Group; Members of ASNC; EANM Committee Coordinator. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging. 2018;45(7):1250–69. doi:.https://doi.org/10.1007/s00259-018-3973-8
  30. Stellingwerff MD, Brouwer E, Lensen KJ, Rutgers A, Arends S, van der Geest KS, et al. Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization. Medicine (Baltimore). 2015;94(37):e1542. doi:.https://doi.org/10.1097/MD.0000000000001542
  31. Puppo C, Massollo M, Paparo F, Camellino D, Piccardo A, Shoushtari Zadeh Naseri M, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. BioMed Res Int. 2014;2014:574248. doi:.https://doi.org/10.1155/2014/574248
  32. Blockmans D. The use of (18F)fluoro-deoxyglucose positron emission tomography in the assessment of large vessel vasculitis. Clin Exp Rheumatol. 2003;21(6, Suppl 32):S15–22.
  33. Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(9):1764–72. doi:.https://doi.org/10.1007/s00259-011-1830-0
  34. Blockmans D, Bley T, Schmidt W. Imaging for large-vessel vasculitis. Curr Opin Rheumatol. 2009;21(1):19–28. doi:.https://doi.org/10.1097/BOR.0b013e32831cec7b
  35. Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30(5):730–6. doi:.https://doi.org/10.1007/s00259-003-1144-y
  36. Hautzel H, Sander O, Heinzel A, Schneider M, Müller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med. 2008;49(7):1107–13. doi:.https://doi.org/10.2967/jnumed.108.051920
  37. Imfeld S, Rottenburger C, Schegk E, Aschwanden M, Juengling F, Staub D, et al. [18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic. Eur Heart J Cardiovasc Imaging. 2018;19(8):933–40. doi:.https://doi.org/10.1093/ehjci/jex259
  38. Kistner A, Bigler MB, Glatz K, Egli SB, Baldin FS, Marquardsen FA, et al. Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis. Rheumatology (Oxford). 2017;56(5):829–34.
  39. Monach PA. Biomarkers in vasculitis. Curr Opin Rheumatol. 2014;26(1):24–30. doi:.https://doi.org/10.1097/BOR.0000000000000009
  40. Schmidt WA, Krause A, Schicke B, Kuchenbecker J, Gromnica-Ihle E. Do temporal artery duplex ultrasound findings correlate with ophthalmic complications in giant cell arteritis? Rheumatology (Oxford). 2009;48(4):383–5. doi:.https://doi.org/10.1093/rheumatology/ken515
  41. Duftner C, Dejaco C, Sepriano A, Falzon L, Schmidt WA, Ramiro S. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4(1):e000612. doi:.https://doi.org/10.1136/rmdopen-2017-000612
  42. Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010;11(1):44. doi:.https://doi.org/10.1186/1471-2474-11-44
  43. Aschwanden M, Imfeld S, Staub D, Baldi T, Walker UA, Berger CT, et al. The ultrasound compression sign to diagnose temporal giant cell arteritis shows an excellent interobserver agreement. Clin Exp Rheumatol. 2015;33(2, Suppl 89):S-113–5.
  44. Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess. 2016;20(90):1–238. doi:.https://doi.org/10.3310/hta20900
  45. Germanò G, Muratore F, Cimino L, Lo Gullo A, Possemato N, Macchioni P, et al. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. Rheumatology (Oxford). 2015;54(3):400–4. doi:.https://doi.org/10.1093/rheumatology/keu241
  46. Monti S, Floris A, Ponte CB, Schmidt WA, Diamantopoulos AP, Pereira C, et al. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology (Oxford). 2018;57(1):112–9. doi:.https://doi.org/10.1093/rheumatology/kex341
  47. Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol. 2005;184(1):283–7. doi:.https://doi.org/10.2214/ajr.184.1.01840283
  48. Rhéaume M, Rebello R, Pagnoux C, Carette S, Clements-Baker M, Cohen-Hallaleh V, et al. High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. Arthritis Rheumatol. 2017;69(1):161–8. doi:.https://doi.org/10.1002/art.39824
  49. Hommada M, Mekinian A, Brillet PY, Abad S, Larroche C, Dhôte R, et al. Aortitis in giant cell arteritis: diagnosis with FDG PET/CT and agreement with CT angiography. Autoimmun Rev. 2017;16(11):1131–7. doi:.https://doi.org/10.1016/j.autrev.2017.09.008
  50. Cinar I, Wang H, Stone JR. Clinically isolated aortitis: pitfalls, progress, and possibilities. Cardiovasc Pathol. 2017;29:23–32. doi:.https://doi.org/10.1016/j.carpath.2017.04.003
  51. Lariviere D, Benali K, Coustet B, Pasi N, Hyafil F, Klein I, et al. Positron emission tomography and computed tomography angiography for the diagnosis of giant cell arteritis: A real-life prospective study. Medicine (Baltimore). 2016;95(30):e4146. doi:.https://doi.org/10.1097/MD.0000000000004146
  52. de Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18F-fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis: A multicenter cohort of 130 patients. Medicine (Baltimore). 2016;95(26):e3851. doi:.https://doi.org/10.1097/MD.0000000000003851
  53. Lee YH, Choi SJ, Ji JD, Song GG. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis. Z Rheumatol. 2016;75(9):924–31. doi:.https://doi.org/10.1007/s00393-015-1674-2
  54. Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore). 2015;94(14):e622. doi:.https://doi.org/10.1097/MD.0000000000000622
  55. Fuchs M, Briel M, Daikeler T, Walker UA, Rasch H, Berg S, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging. 2012;39(2):344–53. doi:.https://doi.org/10.1007/s00259-011-1967-x
  56. Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge EM. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018;45(7):1119–28. doi:.https://doi.org/10.1007/s00259-018-4021-4
  57. Moosig F, Czech N, Mehl C, Henze E, Zeuner RA, Kneba M, et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis. 2004;63(7):870–3. doi:.https://doi.org/10.1136/ard.2003.011692
  58. Cimmino MA, Zampogna G, Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology (Oxford). 2008;47(6):926–7. doi:.https://doi.org/10.1093/rheumatology/ken098
  59. Takahashi H, Yamashita H, Kubota K, Miyata Y, Okasaki M, Morooka M, et al. Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Mod Rheumatol. 2015;25(4):546–51. doi:.https://doi.org/10.3109/14397595.2014.978936
  60. Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 1981;24(11):1414–8. doi:.https://doi.org/10.1002/art.1780241113
  61. Balink H, Veeger NJ, Bennink RJ, Slart RH, Holleman F, van Eck-Smit BL, et al. The predictive value of C-reactive protein and erythrocyte sedimentation rate for 18F-FDG PET/CT outcome in patients with fever and inflammation of unknown origin. Nucl Med Commun. 2015;36(6):604–9. doi:.https://doi.org/10.1097/MNM.0000000000000300
  62. Lensen KJ, Voskuyl AE, van der Laken CJ, Comans EF, van Schaardenburg D, Arntzenius AB, et al. 18F-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin. PLoS One. 2013;8(3):e58917. doi:.https://doi.org/10.1371/journal.pone.0058917
  63. Besson FL, Chaumet-Riffaud P, Playe M, Noel N, Lambotte O, Goujard C, et al. Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. Eur J Nucl Med Mol Imaging. 2016;43(10):1887–95. doi:.https://doi.org/10.1007/s00259-016-3377-6
  64. Dong MJ, Zhao K, Liu ZF, Wang GL, Yang SY, Zhou GJ. A meta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin. Eur J Radiol. 2011;80(3):834–44. doi:.https://doi.org/10.1016/j.ejrad.2010.11.018
  65. Balink H, Tan SS, Veeger NJ, Holleman F, van Eck-Smit BL, Bennink RJ, et al. 18F-FDG PET/CT in inflammation of unknown origin: a cost-effectiveness pilot-study. Eur J Nucl Med Mol Imaging. 2015;42(9):1408–13. doi:.https://doi.org/10.1007/s00259-015-3010-0
  66. Balink H, Verberne HJ, Bennink RJ, van Eck-Smit BL. A Rationale for the Use of F18-FDG PET/CT in Fever and Inflammation of Unknown Origin. Int J Mol Imaging. 2012;2012:165080. doi:.https://doi.org/10.1155/2012/165080
  67. Pfadenhauer K, Weinerth J, Hrdina C. Vertebral arteries: a target for FDG-PET imaging in giant cell arteritis? Clinical, ultrasonographic and PET study in 46 patients. Nucl Med (Stuttg). 2011;50(1):28–32. doi:.https://doi.org/10.3413/nukmed-0335-10-07
  68. Quinn KA, Ahlman MA, Malayeri AA, Marko J, Civelek AC, Rosenblum JS, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77(8):1165–71.
  69. Cimmino MA, Camellino D. Large vessel vasculitis: which imaging method? Swiss Med Wkly. 2017;147:w14405.
  70. de Boysson H, Dumont A, Liozon E, Lambert M, Boutemy J, Maigné G, et al. Giant-cell arteritis: concordance study between aortic CT angiography and FDG-PET/CT in detection of large-vessel involvement. Eur J Nucl Med Mol Imaging. 2017;44(13):2274–9. doi:.https://doi.org/10.1007/s00259-017-3774-5
  71. Einspieler I, Thürmel K, Pyka T, Eiber M, Wolfram S, Moog P, et al. Imaging large vessel vasculitis with fully integrated PET/MRI: a pilot study. Eur J Nucl Med Mol Imaging. 2015;42(7):1012–24. doi:.https://doi.org/10.1007/s00259-015-3007-8
  72. Martinez-Lado L, Calviño-Díaz C, Piñeiro A, Dierssen T, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90(3):186–93. doi:.https://doi.org/10.1097/MD.0b013e31821c4fad
  73. Berger CT, Recher M, Daikeler T. Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis. Rheumatology (Oxford). 2018;57(1):196–7. doi:.https://doi.org/10.1093/rheumatology/kex336
  74. Dikkes A, Aschwanden M, Imfeld S, Glatz K, Messerli J, Staub D, et al. Takayasu arteritis: active or not, that’s the question. Rheumatology (Oxford). 2017;56(10):1818–9. doi:.https://doi.org/10.1093/rheumatology/kex213
  75. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720–9. doi:.https://doi.org/10.1002/acr.21750
  76. Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. 18 F-Fluorodeoxyglucose-Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis Rheumatol. 2018;70(3):439–49. doi:.https://doi.org/10.1002/art.40379
  77. Clifford A, Burrell S, Hanly JG. Positron emission tomography/computed tomography for the diagnosis and assessment of giant cell arteritis: when to consider it and why. J Rheumatol. 2012;39(10):1909–11. doi:.https://doi.org/10.3899/jrheum.120171
  78. Prieto-González S, García-Martínez A, Tavera-Bahillo I, Hernández-Rodríguez J, Gutiérrez-Chacoff J, Alba MA, et al. Effect of glucocorticoid treatment on computed tomography angiography detected large-vessel inflammation in giant-cell arteritis. A prospective, longitudinal study. Medicine (Baltimore). 2015;94(5):e486. doi:.https://doi.org/10.1097/MD.0000000000000486
  79. Reichenbach S, Adler S, Bonel H, Cullmann JL, Kuchen S, Bütikofer L, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology (Oxford). 2018;57(6):982–6. doi:.https://doi.org/10.1093/rheumatology/key015
  80. Scheel AK, Meller J, Vosshenrich R, Kohlhoff E, Siefker U, Müller GA, et al. Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis. 2004;63(11):1507–10. doi:.https://doi.org/10.1136/ard.2003.015651
  81. Schinkel AF, van den Oord SC, van der Steen AF, van Laar JA, Sijbrands EJ. Utility of contrast-enhanced ultrasound for the assessment of the carotid artery wall in patients with Takayasu or giant cell arteritis. Eur Heart J Cardiovasc Imaging. 2014;15(5):541–6. doi:.https://doi.org/10.1093/ehjci/jet243
  82. Herlin B, Baud JM, Chadenat ML, Pico F. Contrast-enhanced ultrasonography in Takayasu arteritis: watching and monitoring the arterial inflammation. BMJ Case Rep. 2015;2015:bcr2015211094. doi:.https://doi.org/10.1136/bcr-2015-211094
  83. Czihal M, Lottspeich C, Schröttle A, Treitl KM, Treitl M, Leipe J, et al. Relapses in three patients with Takayasu arteritis under tocilizumab treatment detected by contrast enhanced ultrasound. Vasa. 2018;47(2):149–52. doi:.https://doi.org/10.1024/0301-1526/a000679
  84. García-Martínez A, Arguis P, Prieto-González S, Espígol-Frigolé G, Alba MA, Butjosa M, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann Rheum Dis. 2014;73(10):1826–32. doi:.https://doi.org/10.1136/annrheumdis-2013-203322
  85. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–31. doi:.https://doi.org/10.1002/art.11353
  86. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83(6):335–41. doi:.https://doi.org/10.1097/01.md.0000145366.40805.f8
  87. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502–7. doi:.https://doi.org/10.7326/0003-4819-122-7-199504010-00004
  88. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989–94. doi:.https://doi.org/10.1136/annrheumdis-2012-202408
  89. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al.; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7. doi:.https://doi.org/10.1093/rheumatology/keq039a
  90. Diamantopoulos AP, Haugeberg G, Lindland A, Myklebust G. The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology (Oxford). 2016;55(1):66–70. doi:.https://doi.org/10.1093/rheumatology/kev289
  91. Maleszewski JJ, Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017;30(6):788–96. doi:.https://doi.org/10.1038/modpathol.2017.10

Most read articles by the same author(s)

1 2 > >>